A Phase 1 Dose Finding Study of the Safety and Pharmacokinetics of XL184 Administered Orally in Combination With Temozolomide and Radiation Therapy in the First Line Treatment of Subjects With Glioblastoma.

Trial Profile

A Phase 1 Dose Finding Study of the Safety and Pharmacokinetics of XL184 Administered Orally in Combination With Temozolomide and Radiation Therapy in the First Line Treatment of Subjects With Glioblastoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs Cabozantinib (Primary) ; Temozolomide (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions
  • Sponsors Exelixis
  • Most Recent Events

    • 20 Nov 2015 Results published in the Cancer
    • 19 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 26 Feb 2013 Planned End Date changed from 1 Dec 2011 to 1 Apr 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top